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Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and 
fatal fibrosing interstitial pneumonia of unknown cause, which is 
limited to the lungs and occurs primarily in older adults. It is 
characterized by progressive dyspnea and irreversible loss of lung 
function [1]. The prognosis is uniformly poor despite heterogeneity 
in disease progression, with an estimated median length of survival 
of 2–5 years. No treatment has been shown to be effective. This 
premise represents the rationale for the development of novel 
drugs targeting the underlying fibroproliferative process, with the 
aim of limiting disease progression and attenuating the decline in 
pulmonary function.  
 
Pirfenidone, a pyridone derivative (5-methyl-1-phenyl-2-[1H]-
pyridone), is an orally bioavailable molecule that has showed 
various anti-inflammatory and anti-fibrotic properties, including 
inhibition of fibroblast proliferation in animal models of lung 
fibrosis and regulation of transforming growth factor-β and tumor 
necrosis factor-α-mediated fibroblast activity in vitro [2–4]. 
Nevertheless, the exact mechanism of action of pirfenidone 
remains to be fully clarified.  
 
Several studies have evaluated the safety and the efficacy of 
pirfenidone in patients with IPF. Azuma and colleagues assessed 
the efficacy of pirfenidone (1800 mg/day) in 107 Japanese patients 
with IPF in a randomized, placebo-controlled Phase II trial, which 
showed a reduced decline in the mean change in vital capacity in 
the treatment arm [5]. These findings led to three Phase III studies 
– one in Japan and two across North America and Europe. The 
results of a Phase III study conducted by Taniguchi et al. led to the 
approval of pirfenidone for the treatment of IPF in Japan [6]. On 
the other hand, the CAPACITY program included two similar 
international trials (PIPF-004 and PIPF-006) in 110 centers across 
North America, Australia, and Europe [7]; the data from these 
trials indicated that pirfenidone reduced the decline in forced vital 
capacity (FVC) and had a favorable benefit/risk profile, and 
therefore represents an appropriate treatment option for patients 
with IPF. The first of these studies, PIPF-004, was a Phase III 
randomized, placebo-controlled, 72-week trial that had three arms: 
high-dose pirfenidone (2403 mg/day), low-dose pirfenidone (1197 
mg/day), and placebo. Enrollment proceeded in a 2:1:2 ratio and 
included a primary outcome of absolute percentage change in 
predicted FVC between enrollment and week 72. At week 72, 
pirfenidone 2403 mg/day significantly reduced the mean decline in 
percent-predicted FVC, compared with placebo (-8.0% vs. -12.4 
%, respectively), and the proportion of patients with FVC declines 
of >10%.  
 
The 72-week Phase III trial PIPF-006 was undertaken in order to 
expand these promising results, comparing the effect of high-dose 
pirfenidone to placebo with randomization in a 1:1 ratio. 
Unfortunately, at the end of the study a beneficial effect on the 
primary endpoint of decline in percent-predicted FVC was not 
achieved (p=0.501), but further analysis revealed that this was 
because of a more-robust placebo effect. Altogether, the treatment 
effect was significant at weeks 12, 24, 36, and 48.  
 
The safety profile of pirfenidone is excellent, and it appears to be 
generally well tolerated. The most common side effects in the 
Phase II and Phase III trials were gastrointestinal upset, fatigue, 
nausea, anorexia, and dermatological problems, including 
photosensitivity. Despite these adverse events, the number of 
patients who discontinued the drug was low. 
Case report 
A 77-year-old, non-smoking, Italian female with an allergy to 
acetylsalicylic acid and who was affected by anxious–depressive 
syndrome presented with dry cough in June 2006, followed by the 
onset of exertional dyspnea in October of the same year. Because 
of worsening of her dyspnea, the patient underwent a chest X-ray 
that showed a consolidation (compatible with the diagnosis of 
bronchopneumonia), which was effectively treated with antibiotics 
and steroids. The following chest X-ray showed clearing of the 
area of consolidation, but cough and breathlessness persisted.  
 
Therefore, on 28 February 2007 the patient underwent a high-
resolution computed tomography scan of the chest, which showed 
evidence in three different basal lung regions of diffuse interstitial 
lung disease characterized by predominantly bibasal and peripheral 
reticular opacities, traction bronchiectasis, honeycomb lung 
destruction, and irregular areas of consolidation with no ground 
glass opacities (Figure 1). The pattern was considered to be 
consistent with usual interstitial pneumonia. In order to exclude 
other known causes of pulmonary fibrosis, a bronchoscopy with 
bronchoalveolar lavage was performed and did not provide 
evidence for alternative diagnoses. Based on the patient’s clinical 
history, other secondary causes of interstitial lung disease (such as 
connective tissue diseases or drug toxicity) were also excluded. 
Thus, a diagnosis of IPF was finally set. At this point, the patient 
agreed to enrolment in the PIPF-004 clinical trial. In May 2007, 
she started treatment with the pirfenidone at the dose of 2403 
mg/day, divided into three tablets three times a day.  
 
In June 2007, after 6 weeks of treatment, the patient reported a 
reduction in cough symptoms and decreased appetite. Between 
June and September 2007, she showed subjective improvement in 
respiratory symptoms and a further reduction in cough.  
 
In October 2007, the patient came to our attention for an 
unscheduled visit because of the onset of general malaise, 
hypotension, dizziness, and anorexia, with altered perception of 
smell and taste. As a consequence of these adverse events, most 
likely due to the patient’s intolerance to the highest dosage of the 
pirfenidone, the dosage was reduced to 1800 mg/day, divided into 
two tablets three times a day.  
 
Nevertheless, at week 24 of the study, the patient’s clinical 
conditions were further improved, meaning that the reduced drug 
dosage still had an effect on the patient’s symptoms. Sporadic 
episodes of tracheitis, pharyngitis, bronchitis, and labyrinthitis 
occurred, but all of these were effectively treated.  
 
During the study, the patient underwent several follow-up visits in 
which pulmonary function tests with diffusing lung capacity for 
carbon monoxide were performed, together with blood tests, a 6-
min walking test, and electrocardiogram. The University of 
California, San Diego Shortness of Breath questionnaire, the St 
George’s Respiratory Questionnaire and the World Health 
Organization Quality of Life-100 questionnaire were used at the 
beginning of the trial to gain information about dyspnea and 
quality of life. At the end of the PIPF-004 study, the patient’s 
clinical conditions were stable and good, notwithstanding the 
persistence of bibasal, bilateral, Velcro-type crackles.  
 
In October 2008, the patient was included in the PIPF-012 rollover 
study. Until March 2012 the patient underwent follow-up visits at 
our center in Modena, Italy, with quarterly assessment of 
pulmonary function and blood tests. During nearly 4 years of 
additional follow-up the patient did not present any other side-
effect related to pirfenidone, nor any acute exacerbations of IPF. 
Nevertheless, other sporadic episodes of pharyngitis and bronchitis 
occurred, but these were all effectively treated with antibiotics. In 
March 2012, the PIPF-012 study ended; given the persistent 
stability of her clinical condition, the patient was admitted to 
continue receiving pirfenidone under the European Named Patient 
Program upon approval by the local ethics committee.  
 
Since May 2007, the patient did not present any clinically 
significant impairment in her lung function parameters, with 
substantial stability in FVC. Data from pulmonary function tests 
(one for each year from May 2007 to March 2012) are shown in 
Table 1. These results are better than that expected from the 
published results of the CAPACITY trials; nevertheless, it is not 
known whether this functional stability is related to the efficacy of 
pirfenidone, as it could also be because of the favorable course of 
the fibrotic process, or the natural history of the disease for this 
particular patient. On the other hand, the hypothesis of a drug-
related benefit is supported by the improvement in respiratory 
symptoms experienced by the patient from a few weeks after 
starting treatment with pirfenidone, and continuing after the dosage 
reduction from 2400 mg/day to 1800 mg/day; this means that 1800 
mg/day could be considered as the lowest effective dosage for this 
patient.  
 
The patient has suffered from some of the most frequent adverse 
events reported for pirfenidone in the CAPACITY trials, such as 
general malaise, anorexia, and gastrointestinal symptoms. These 
effects disappeared with the reduction of the drug dosage from 
2400 mg/day to 1800 mg/day, confirming the good tolerability of 
pirfenidone.  
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